Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Energous expects to report revenue for the quarter ended June 30, 2025, totaling in excess of $900,000, and expects to deliver the lowest quarterly net loss in the last ten years.

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Viking Therapeutics has begun the VANQUISH Phase III clinical programme of VK2735, intended for the potential treatment of obesity.

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to ...

Stocktwits - Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company’s presentation of pharmacology modeling data, which showed investigational antibody ...

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to ...